PRESS RELEASE published on 06/05/2024 at 07:30, 5 months 16 days ago OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant OSE Immunotherapeutics and Nantes University Hospital present positive Phase 1/2 study evaluating FR104/VEL-101 immunotherapy in renal transplant at American Transplant Congress 2024 Immunotherapy Phase 1/2 Study OSE Immunotherapeutics Nantes University Hospital Renal Transplant
PRESS RELEASE published on 06/05/2024 at 07:30, 5 months 16 days ago OSE Immuno et le Centre Hospitalier Universitaire de Nantes présentent une analyse positive de l’essai clinique de Phase 1/2 évaluant l’immunothérapie FR104/VEL-101 en transplantation rénale OSE Immunotherapeutics et le Centre Hospitalier Universitaire de Nantes présentent une analyse positive de l'essai clinique de Phase 1/2 évaluant l'immunothérapie FR104/VEL-101 en transplantation rénale au congrès 'American Transplant Congress' 2024 Essai Clinique OSE Immunotherapeutics Transplantation Rénale FR104/VEL-101 Centre Hospitalier Universitaire De Nantes
BRIEF published on 05/22/2024 at 07:35, 5 months 30 days ago OSE Immunotherapeutics et Boehringer Ingelheim étendent leur collaboration pour de nouveaux traitements Collaboration Immunothérapie Cancer Cardio-rénal-métabolique
BRIEF published on 05/22/2024 at 07:35, 5 months 30 days ago OSE Immunotherapeutics and Boehringer Ingelheim Expand Collaboration for Novel Treatments Collaboration Immunotherapy Cancer Cardio-renal-metabolic
PRESS RELEASE published on 05/22/2024 at 07:30, 5 months 30 days ago OSE Immunotherapeutics et Boehringer Ingelheim étendent leur collaboration pour développer des traitements first-in-class dans le cancer et dans les maladies cardiovasculaires, rénales et métaboliques OSE Immunotherapeutics et Boehringer Ingelheim étendent leur collaboration pour développer des traitements innovants dans le cancer et les maladies CVRM. Deux nouveaux projets first-in-class annoncés renforcent le portefeuille de Boehringer Ingelheim Cancer Boehringer Ingelheim OSE Immunotherapeutics Traitements Innovants Maladies CVRM
PRESS RELEASE published on 05/22/2024 at 07:30, 5 months 30 days ago OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases OSE Immunotherapeutics and Boehringer Ingelheim expand partnership to develop first-in-class therapies for cancer and cardio-renal-metabolic diseases, aiming to address unmet patient needs Partnership Cancer Boehringer Ingelheim OSE Immunotherapeutics First-in-class Treatments
PRESS RELEASE published on 05/26/2023 at 08:15, 1 year 5 months ago OSE Immunotherapeutics (OSE): Re-initiation – Milestones anticipated throughout FY23
Published on 11/21/2024 at 12:00, 36 minutes ago Alset AI Announces Full Repayment of $3.7 Million Secured Loan with Interest from Portfolio Company, Significantly Strengthening Balance Sheet
Published on 11/21/2024 at 12:00, 36 minutes ago Battery X Metals Commences Strategic Initiatives to Strengthen Balance Sheet
Published on 11/21/2024 at 11:30, 1 hour 6 minutes ago FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 2 hours 33 minutes ago Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 2 hours 36 minutes ago BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 12:15, 21 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 11:30, 1 hour 6 minutes ago APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived
Published on 11/21/2024 at 11:01, 1 hour 35 minutes ago Original-Research: SMT Scharf AG (von Montega AG): Kaufen
Published on 11/21/2024 at 06:58, 5 hours 38 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 38 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 38 minutes ago Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 16 hours 28 minutes ago Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 17 hours 16 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting